Amylyx reports positive Phase 3 LUCIDITY topline result
The 78-patient randomized trial met its FDA-agreed primary endpoint, but the efficacy figures are the company's own topline claim — not yet peer-reviewed or approved by regulators.
The 60-second version
Amylyx's avexitide met its Phase 3 LUCIDITY primary endpoint with a company-reported 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events (p=0.000003) in post-bariatric hypoglycemia — a condition with no FDA-approved treatment — but the result is not yet peer-reviewed or approved.
Key points
- ⚑ LUCIDITY is a 78-patient, randomized, double-blind, placebo-controlled Phase 3 trial of avexitide (90 mg SC daily) in post-bariatric hypoglycemia (PBH) after RYGB surgery.
- ⚑ The primary endpoint — composite rate of Level 2 and Level 3 hypoglycemic events — showed a 55% reduction vs placebo (p=0.000003); all secondary endpoints also met statistical significance.
- ⚑ Amylyx plans to submit an NDA by end of 2026; avexitide has FDA Breakthrough Therapy and Orphan Drug Designations that could accelerate review.
- The results are company topline claims — not peer-reviewed, not published. Granular secondary endpoint figures have not been disclosed.
- ⚑ Avexitide was acquired from Eiger BioPharmaceuticals in a 2024 bankruptcy sale (~$35M). The PBH pipeline remains sparse, with competitors still in early-stage development.
Verdict. The LUCIDITY results are the strongest clinical signal yet for a targeted PBH treatment, but they remain company-reported topline data. The true test will be the FDA's NDA review and independent peer evaluation.
The headlineA 55% reduction in the composite event rate
On August 18, 2026, Amylyx Pharmaceuticals announced positive topline results from LUCIDITY, a Phase 3 clinical trial of avexitide in post-bariatric hypoglycemia (PBH). The 78-patient, multicenter, randomized, double-blind, placebo-controlled study met its FDA-agreed-upon primary endpoint, showing a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003).
PBH is a chronic metabolic condition estimated to affect roughly 160,000 people in the United States after the two most common bariatric surgeries, including sleeve gastrectomy and Roux-en-Y gastric bypass (RYGB). After a meal, these patients experience an exaggerated release of GLP-1, which drives excessive insulin secretion and causes blood glucose to crash — sometimes to dangerous levels requiring emergency assistance.
There is currently no FDA-approved treatment for PBH. Patients rely entirely on off-label drugs — acarbose, diazoxide, and octreotide — none of which target the GLP-1-driven pathophysiology specific to the condition.
The trialLUCIDITY: design and execution
Registered as NCT06747468 on ClinicalTrials.gov, LUCIDITY enrolled 78 adults with PBH following RYGB surgery. Participants were randomized 3:2 to receive either 90 mg of avexitide subcutaneously once daily or matching placebo, across 21 sites in the United States.
| Trial name | LUCIDITY (AVX-001) |
|---|---|
| Phase | 3 |
| Design | Multicenter, randomized, double-blind, placebo-controlled |
| Participants | 78 adults with PBH after RYGB per Amylyx topline release; registry lists estimated enrollment of 75 |
| Randomization | 3:2 (avexitide 90 mg SC daily vs placebo) |
| Duration | 16 weeks double-blind; 32-week OLE ongoing |
| Primary endpoint | Composite rate of Level 2 (SMBG) and Level 3 (adjudicated) hypoglycemic events |
| Sponsor | Amylyx Pharmaceuticals Inc. |
| Enrollment period | April 2025 – March 2026 |
| Sites | 21 US centers |
The numbersWhat the company reported
Amylyx states that LUCIDITY met the primary endpoint with a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events (p=0.000003). The company also reports that all secondary endpoints were met, showing consistent and clinically meaningful reductions in:
- Level 2 hypoglycemic events measured by self-monitoring of blood glucose (SMBG)
- Level 2 hypoglycemic events measured by continuous glucose monitoring (CGM)
- Level 3 (severe) hypoglycemic events, independently adjudicated by an Event Adjudication Committee
Safety profileGenerally well-tolerated
Avexitide was generally well-tolerated through the double-blind period. The majority of adverse events were mild to moderate. The most common were diarrhea, injection site erythema, and injection site bruising. No serious adverse events were attributed to avexitide treatment, and no body weight changes were observed in either group.
What comes nextNDA, approval timeline, and competition
Amylyx plans to submit a New Drug Application (NDA) to the FDA by the end of 2026. The FDA previously granted avexitide Breakthrough Therapy Designation for PBH and Orphan Drug Designation for hyperinsulinemic hypoglycemia, which could accelerate the review process. If approved, the company targets a commercial launch in 2027.
Avexitide has an unusual backstory. Amylyx acquired the asset through a bankruptcy sale from Eiger BioPharmaceuticals in 2024 for approximately $35 million. Eiger had advanced avexitide through Phase II before filing for Chapter 11 protection. The LUCIDITY open-label extension (32 weeks) and an expanded access program launched in May 2026 remain ongoing.
The PBH pipeline is sparse but not empty. Vogenx is advancing the SGLT1 inhibitor mizagliflozin toward a Phase IIb study. MBX Biosciences' imapextide (MBX-1416), a long-acting GLP-1 receptor antagonist and a more direct competitor, has entered Phase IIa. Both programs remain substantially behind avexitide. Amylyx also has a preclinical next-generation GLP-1 antagonist, AMX0318, in IND-enabling studies, with an IND filing targeted for 2027.
The bottom lineSignificant signal, but not yet proven
A 55% reduction with a p-value of 0.000003 in a well-designed Phase 3 trial is a strong signal, especially for a condition with no approved treatment. But a few important caveats remain: the results are company-reported and not yet peer-reviewed; the trial enrolled only 78 patients; and the granular secondary endpoint data have not been disclosed. The FDA's review of the planned NDA will be the real test.